Neumora Therapeutics’ Experimental Drug Demonstrates Weight Loss in Preclinical Studies

• Neumora said that NMRA-215 demonstrated weight loss of up to 19% as a monotherapy and 26% in combination with semaglutide.
• The company now plans to initiate an early-stage clinical study for the experimental drug in the first quarter of 2026.
   

Neumora Therapeutics, Inc. (NMRA) on Monday announced positive data from preclinical studies for its experimental weight-loss therapy NMRA-215.

The company said that NMRA-215 demonstrated weight loss of up to 19% as a monotherapy and 26% in combination with Semaglutide in mice with diet-induced obesity. Semaglutide is the active ingredient in Novo Nordisk’s (NVO) popular weight-loss drug Wegovy.

Plans Ahead

NMRA-215 is an oral NLRP3 inhibitor in development for the treatment of obesity. It blocks the activity of the NLRP3 inflammasome, a protein complex involved in the immune response to inflammation. NLRP3-mediated neuroinflammation in the hypothalamus is linked to obesity, Neumora noted.

The company now plans to initiate an early-stage clinical study for the experimental drug in the first quarter of 2026.

How Did Stocktwits Users React?

Shares of the company jumped about 22% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around NMRA stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.

“These data demonstrate NMRA-215 drives meaningful weight loss as a monotherapy in mice, including incretin-like induction, additive weight loss in the combination setting with semaglutide, as well as the potential to enable incretin-sparing dosing regimens.”
– Paul Berns, CEO, Neumora Therapeutics

Separately, Neumora on Monday also announced the initiation of an early-stage study of its NMRA-898 aimed at evaluating safety, tolerability, and human pharmacokinetic data of the compound for potential use in the treatment of schizophrenia and other neuropsychiatric disorders. 

NMRA stock is down by 75% this year and by about 78% over the past 12 months. 

Read also: Ethereum Outperforms Bitcoin As Retail Sentiment Improves Ahead Of Fed Rate Decision, Trump-Xi Meeting This Week

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on